Report Buyer Adds Advisory Report for Ethical Pharmaceutical Companies Fighting Generics

July 2, 2008 - PRLog -- Report Buyer has added a new report examining the vulnerable situation that ethical pharmaceutical companies have found themselves in as a result of new threat posed by generic drugs.

The report “Generics Threats and Opportunities: Mounting an Effective Defense Strategy”, which is available at http://www.reportbuyer.com/go/CAB000002 analyses the seismic shift which the pharmaceutical industry has undergone after years of relatively easy blockbuster profits, worldwide respect and investment, and loyal customer bases.

Offering an explanation behind the emergence of generics as the primary challenger to pharmaceutical industry success, the report explains how generics have exploded in the last decades while the Pharmaceutical Industry gets squeezed by internal and external pressure, customers, physicians and governments.

The reasons for the pharmaceutical industry’s vulnerability are many, but one culprit is the increasing requirements to create medication. Researching and developing a commercial prescription drug today requires an average total investment of $500 Million and 10 - 15 years of lab work, clinical trials and extensive regulatory review. When the drug is finally out in the marketplace, it enjoys only a brief period of monopoly and profit before patent expiration and plummeting market share in the face of a generic takeover.

With the lower prices and operating costs the allow the generic drug industry to gain an advantage, the future looks uncertain for Pharmaceutical companies. There are options that can be used to create an effective defence strategy to combat this new threat.

The report, authored by Dr Andree Bates, examines some of these defensive strategies. It analyses the environment for pharmaceuticals today, as well as the generic industry as a whole, and describes the pros and cons of legal defensive strategies as well as opportunities to expand the revenue-generating product life cycle into reformulations and over-the-counter medications.

Furthermore, the report looks at pricing strategies as well as company organisational changes as part of an integrated defence strategy. Assisting companies in making decisions about the best defence, authors of the report examine powerful analytics techniques and case studies.

“Generics Threats and Opportunities: Mounting an Effective Defense Strategy” is priced at £495 and is available from Report Buyer at: http://www.reportbuyer.com/pharma_healthcare/generic_drug...

Report Buyer product ID: CAB00002

# # #

About Report Buyer.
Report Buyer is a UK-based independent online store supplying business information. The website now carries over 79,000 business information products, including market reports, studies, books and events. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.